THE PROSPECTS FOR THE USE OF microRNA AS DIAGNOSTIC AND PROGNOSTIC MELANOMA BIOMARKERS-Reference-Cited by-同舟云学术

THE PROSPECTS FOR THE USE OF microRNA AS DIAGNOSTIC AND PROGNOSTIC MELANOMA BIOMARKERS

Published:2019-12-02 Issue:4 Volume:18 Page:51-56
ISSN:1726-9792
Container-title:Russian Journal of Biotherapy
language:
Short-container-title:Rossijskij bioterapevtičeskij žurnal

Author:

Chulkova S. V.¹^ORCID,Ryabchikov D. A.²^ORCID,Dudina I. A.³,Kazakov A. M.⁴,Egorova A. V.⁵,Titov K. S.⁶^ORCID,Khagazheeva M. N.⁴,Gladilina I. A.¹,Galaeva Z. M.⁵,Lepkova N. V.⁵,Tupitsyn N. N.⁴

Affiliation:

1. N. N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation; N. I. Pirogov Russian National Research Medical University

2. 1N. N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

3. FSBI FNKC FMBA of Russia

4. N. N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

5. N. I. Pirogov Russian National Research Medical University

6. MCSC the Loginov Moscow Clinical Scientific Center Is State Institution Funded By Moscow Health Department

Abstract

Despite recent advances in targeted and immune therapy, 5‑year overall survival in stages III–IV of melanoma is 50 and 10–20 %, respectively. Modern melanoma biomarkers, which are used in clinical practice, are not sufficiently effective for early diagnosis and prognosis assessment. In the last decade, circulating microRNAs (miRNAs) have come to be regarded as “ideal” melanoma biomarkers. This article presents the characteristics of miRNA biogenesis, as well as provides a critical review of circulating miRNAs as promising diagnostic and prognostic melanoma biomarkers.

Publisher

Publishing House ABV Press

Reference40 articles.

1. Mumford S.L., Towler B.P., Pashler A.L. et al. Circulating MicroRNA biomarkers in melanoma: tools and challenges in personalised medicine. Biomolecules 2018;8(2):21. DOI: 10.3390/biom8020021.

2. Cancer Research UK Melanoma Survival (accessed on 13 January 2018). Available on: http://www. cancerresearchuk.org/about-cancer/melanoma/survival.

3. Finck S.J., Giuliano A.E., Morton D.L. LDH and melanoma. Cancer 1983;51(5):840–3. DOI: 10.1002/1097-0142(19830301)51: 5<840::AID-CNCR28205-10516>3.0.CO;2-7.

4. Deichmann M., Benner A., Bock M. et al. S100-β, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999;17(6):1891–6. DOI: 10.1200/JCO.1999.17.6.1891.

5. Karonidis A., Mantzourani M., Gogas H., Tsoutsos D. Serum S100-β levels correlate with stage, N status, mitotic rate and disease outcome in melanoma patients independent to LDH. J Buon 2017;22(5):1296–302.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DIAGNOSIS OF MELANOMA: CURRENT STATE AND PROSPECTS (literature review);Clinical Medicine and Pharmacology;2023-12-26

2. DIAGNOSIS OF SKIN MELANOMA: CURRENT STATUS AND PROSPECTS (literature review);Clinical Medicine and Pharmacology;2023-05-15

3. SURGICAL ASPECTS TREATMENT OF SKIN MELANOMA (literature review);Clinical Medicine and Pharmacology;2023-05-15

4. MicroRNA-34a in cardiovascular disease: a glimpse into the future;Kardiologicheskii vestnik;2023

5. The role of molecular genetic factors in the development of cholangiocellular cancer: A review;Journal of Modern Oncology;2022-07-15